1VIRO

LOG

YPRESENTED

BY:-RIDA

KHURSHID

MINA

TAYYAB

2

3

“Ebola is one of the

most deadly

infections known,

killing 90 percent

of people infected

by it”

4

INCI

DEN

CE

OF

EBO

LA V

IRU

S

55

HIS

TORY

6

Firstly recognized in 1976

"Ebola" came from a river in the Democratic Republic of the Congo (formerly Zaire)

18 confirmed outbreaks of the disease since 1976

Ebola was first emerged in Sudan and Zaire

7

8

Infected over 284 people, with a mortality rate of 53%

Second Ebola virus emerged from Yambuku, Zaire, Ebola-Zaire (EBOZ)

EBOZ, with the highest mortality rate of any of the Ebola viruses (88%)

Infected 318 people

9

Ebola Reston (EBOR), was first identified in 1989 when infected

monkeys were imported into Reston, Virginia, from Mindanao in the Philippines

Infected people with EBOR never developed EHF

Ebola Cote d'Ivoire (EBO-CI) was discovered in 1994

1010

CLAS

SIFI

CATI

ON

11

• Group: Group V(-ss RNA)–Order: Mononegavirales•Family: Filoviridae–Genus: Ebolavirus»Species: Zaire ebolavirus

 

Classification of Zaire ebolavirus

12

2010 ICTV report6 Orders87 Families19 Subfamilies348 Genera 2285 Species of viruses

131313STRU

CTU

RE

14

15151515

GEN

OM

E

16

1717

TYPE

S

18

Mainly there are four types ofebola virus:

Ebola-Zaire

  First known outbreak of Ebola HF in humans was caused by Ebola-Zaire This strain surfaced again in southeren Zaire but only one person died

Ebola-Sudan

   Discovered in south western Sudan in 1976 and 1979

19

Ebola-Reston    Strain of Ebola Virus found in monkeys imported in to the US in 1989. Has not caused infection in humans

Ebola-Ivory Coast    Most recently discovered strain of Ebola virus. Found in Tai forests of Ivory Coast in West Africa

20

Filoviruses are classified as biosafety level 4 agents

They are extremely pathogenic

The swift and high lethality of the Ebola virus makes it an attractive potential bioterrorism agent

21

Ebola Hemorrhagic Fever (Ebola HF) carries a 53%- 88% mortality rate

The incubation period is 2-21 days

A severe and often deadly illness that can occur in humans and in primates (monkeys, gorillas)

EHF

2222

REPL

ICAT

ION

23

24

TRAN

SMIS

SIO

N

25

Direct Contact With an Infected Person

burial ceremony

Exposure to Infected Body Fluids

contaminated blood, organs, semen or other bodily secretions

26

27

28

IS IT AIRBORNE….???

Report in ProMED

Reston strain appears airborne but is not known to be harmful to humans

It is hypothesized that the Ebola virus became

"airborne" by being caught inside small droplets of water

that the control monkeys eventually breathed

2929

IMM

UN

E RE

SPO

NSE

30

31

VIRUS INVADE HOST CELL

SYNTHESIS OF RNA FOR REPLICATIO

N

HOST CELL SENSES RNA

ACTIVATION OF HOST

ANTI-VIRAL DEFENSES

CLEARANCE OF VIRAL

INFECTION

MASKING OF REPLICATING RNA VIA VP35 EBOLA PROTEIN

HOST CELL DOESNOT RECOGNIZE INVADING VIRUS

32

The question with Ebola has always been:-

“Why can’t host cells mount an immune response against the

Ebola virus, like they do against other viruses?”

The answer is:-

“If the cell doesn’t know that there’s an infection, it cannot

build up any response.”

33

34SYM

PTO

MS

35

Sore throat Fever Dry, hacking

cough Weakness

Severe headache Joint and

muscle aches Diarrhea

Dehydration Stomach pain Vomiting A rash Hiccups Red eyes Internal and

external bleeding

36

37

Symptoms begin 4 to 6 days after infection

Death usually occurs during the second week of symptoms

Ebola victims typically die from massive blood loss

38DIA

GN

OSI

S

39

For diagnosing Ebola doctor will ask questions which are:-

Symptoms Current medical conditions Family history of medical conditions Current medications

Other medical conditions which can cause similar symptoms to Ebola are:

Influenza Malaria Typhoid fever Other viral hemorrhagic fevers

40

41

IgG ELISA

IgM ELISA distinguishes acute infections from old infections

 IFA is highly misleading

Electron microscopy

Laboratory findings include: Maculopapular rash Lymphopenia and neutrophilia Thrombocytopenia and abnormal platelet aggregation Serum enzyme levels are elevated;  AST is usually higher than ALT  Alkaline phosphatase and bilirubin levels are usually normal or only mildly elevated

42TREA

TMEN

T

43

There is no specific treatment

Supportive therapy involves providing relief of Ebola symptoms while body fights infection

44

Use of Intravenous fluids

Oxygen and devices that help with breathing

Medications to control fever, help the blood clot, and maintain blood pressure

Use of Antibiotics

Good nursing care

45PREV

ENTI

ON

46

There is no Ebola vaccine that is currently licensed, its prevention focuses on:-

Preventing direct contact with infected body fluids

Avoiding direct contact with the body of an Ebola victim

47

Ebola isolation precautions or barrier nursing techniques includes:-

The use of infection-control measures, including complete sterilization of equipment

The isolation of patients with Ebola from contact with unprotected people

The wearing of protective clothing, such as masks, gloves, gowns, and goggles

48

“THE NEW DISCOVERY

INDICATES THE CHANCES HAVE

BEEN IMPROVED FOR THE DRUG

DEVELOPMENT TO DIRECTLY COMBAT EBOLA INFECTION”